How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...
View the basic RXRX option chain and compare options of Recursion Pharmaceuticals, Inc. on Yahoo Finance.
Recursion Pharmaceuticals insiders reported 6 transactions totaling $589,430.56. Activity included 2 tax payments, 2 sales, and 2 stock awards between July and August 2026. View more Major Holders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results